Download PDF
Zentralbl Chir 2008; 133(5): 468-472
DOI: 10.1055/s-2008-1076973
Übersicht

© Georg Thieme Verlag Stuttgart ˙ New York

Selektion zur Peritonektomie mit hyperthermer intraoperativer Chemotherapie (HIPEC) bei Peritonealkarzinose

Selection Criteria for Peritonectomy with Hyperthermic Intraoperative Chemotherapy (HIPEC) in Peritoneal CarcinomatosisI. Königsrainer1 , P. Aschoff2 , D. Zieker1 , S. Beckert1 , J. Glatzle1 , C. Pfannenberg2 , S. Miller2 , J. T. Hartmann3 , T. H. Schroeder4 , B. L. D. M. Brücher1 , A. Königsrainer1
  • 1Klinik für Allgemeine, Viszeral- und Transplantationschirurgie, Tübingen
  • 2Radiologische Klinik, Tübingen
  • 3Medizinische Klinik und Poliklinik II: Hämatologie, Onkologie, Immunologie, Rheumatologie und Pulmologie, Tübingen
  • 4Klinik für Anästhesiologie und Intensivmedizin am Universitätsklinikum Tübingen
Further Information

Publication History

Publication Date:
15 October 2008 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Einleitung: Die Peritonektomie mit hyperthermer intraoperativer Chemotherapie (HIPEC) etabliert sich zunehmend als Therapieoption bei Patienten mit peritoneal metastasierten gastrointestinalen und gynäkologischen Tumoren sowie primären peritonealen Malignomen. Um unnötige Operationen zu vermeiden, sind verlässliche Selektionskriterien unerlässlich. Methoden: Anhand einer Literaturübersicht und eigener Erfahrungen werden Selektionskriterien diskutiert, präoperativ die Operabilität abzuschätzen. Resultate: Die Computertomografie (CT) und die explorative Laparoskopie sind für die Evaluierung einer Peritonealkarzinose unzureichend. Die diagnostische Genauigkeit kann durch die Kombination der Fluor-Deoxyglukose-Positronen-Emissions-Tomografie (FDG-PET) mit dem CT verbessert werden und ist wesentlicher Bestandteil des eigenen diagnostischen Algorithmus. Schlussfolgerung: Das PET / CT gilt in unseren Händen derzeit wohl als sicherstes nicht invasives Verfahren zur Abschätzung der Operabilität. 

Abstract

Background: Cytoreductive peritonectomy with hyperthermic intraoperative chemotherapy (HIPEC) is an established therapy for patients with gastrointestinal, gynaecological metastasised peritoneal carcinomatosis as well as primary peritoneal carcinomatous tumours. Methods: On the basis of a literature review and our personal experience, selection criteria for peritonectomy are discussed. Results: Computed tomography (CT) scans and diagnostic laparoscopy are not sufficient for the diagnosis of peritoneal carcinomatosis. The combination of fluorodeoxyglucose positron emission tomography (FDG-PET) and CT seems to be the most reliable diagnostic imaging method. In our institution, all patients undergo PET / CT prior to peritonectomy. Conclusion: The PET / CT scan may play an important role in forecasting the operability of patients with peritoneal carcinomatosis. 

Schlüsselwörter

Peritonealkarzinose - Selektionskriterien - PET / CT - präoperative Evaluation

Key words

peritoneal carcinomatosis - selection criteria - preoperative evaluation - PET / CT scan

Literatur

  • 1 Antoch G, Saoudi N, Kuehl H et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET / CT) for tumor staging in solid tumors: comparison with CT and PET.  J Clin Oncol. 2004;  22 4357-4368
    CrossrefPubMedGoogle Scholar
  • 2 Armstrong D K, Bundy B, Wenzel L et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.  N Engl J Med. 2006;  354 34-43
    CrossrefPubMedGoogle Scholar
  • 3 Berger K L, Nicholson S A, Dehdashti F et al. FDG-PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features.  AJR Am J Roentgenol. 2000;  174 1005-1008
    CrossrefPubMedGoogle Scholar
  • 4 Coakley F V, Choi P H, Gougoutas C A et al. Peritoneal metastases: detection with spiral CT in patients with ovarian cancer.  Radiology. 2002;  223 495-499
    CrossrefPubMedGoogle Scholar
  • 5 De Bree E, Koops W, Kröger R et al. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement.  J Surg Oncol. 2004;  86 64-73
    PubMedGoogle Scholar
  • 6 Dromain C, Leboulleux S, Auperin A et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET / CT.  Abdom Imaging. 2007;  33 87-93
    PubMedGoogle Scholar
  • 7 Esquivel J, Sticca R, Sugarbaker P et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology.  Ann Surg Oncol. 2007;  14 128-133
    PubMedGoogle Scholar
  • 8 Esquivel J, Vidal-Jove J, Steves M A et al. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy.  Surgery. 1993;  113 631-636
    PubMedGoogle Scholar
  • 9 Feldman A L, Libutti S K, Pingpank J F et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.  J Clin Oncol. 2003;  21 4560-4567
    PubMedGoogle Scholar
  • 10 Glehen O, Mithieux F, Osinsky D et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.  J Clin Oncol. 2003;  21 799-806
    CrossrefPubMedGoogle Scholar
  • 11 Glehen O, Osinsky D, Cotte E et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures.  Ann Surg Oncol. 2003;  10 863-869
    CrossrefPubMedGoogle Scholar
  • 12 Harmon R L, Sugarbaker P H. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer.  Int Semin Surg Oncol. 2005;  8 2-3
    PubMedGoogle Scholar
  • 13 Havrilesky L J, Kulasingam S L, Matchar D B et al. FDG-PET for management of cervical and ovarian cancer.  Gynecol Oncol. 2005;  97 183-191
    CrossrefPubMedGoogle Scholar
  • 14 Huebner R H, Park K C, Shepherd J E et al. A meta-analysis of the literature for whole-body FDG-PET detection of recurrent colorectal cancer.  J Nucl Med. 2000;  41 1177-1189
    PubMedGoogle Scholar
  • 15 Jacquet P, Jelinek J S, Steves M A et al. Evaluation of computed tomography in patients with peritoneal carcinomatosis.  Cancer. 1993;  72 1631-1636
    CrossrefPubMedGoogle Scholar
  • 16 Jacquet P, Jelinek J S, Chang D et al. Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery.  J Am Coll Surg. 1995;  181 530-538
    PubMedGoogle Scholar
  • 17 Jacquet P, Stephens A D, Averbach A M et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy.  Cancer. 1996;  77 2622-2629
    CrossrefPubMedGoogle Scholar
  • 18 Jacquet P, Sugarbaker P H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.  Cancer Treat Res. 1996;  82 359-374
    PubMedGoogle Scholar
  • 19 Kianmanesh R, Scaringi S, Sabate J M et al. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases.  Ann Surg. 2007;  245 597-603
    CrossrefPubMedGoogle Scholar
  • 20 Look M, Chang D, Sugarbaker P H. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum.  Int J Gynecol Cancer. 2003;  13 764-70
    CrossrefPubMedGoogle Scholar
  • 21 Moran B J, Cecil T D. The etiology, clinical presentation, and management of pseudomyxoma peritonei.  Surg Oncol Clin N Am. 2003;  12 585-603
    CrossrefPubMedGoogle Scholar
  • 22 Moran B J, Mukherjee A, Sexton R. Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy.  Br J Surg. 2006;  93 100-104
    CrossrefPubMedGoogle Scholar
  • 23 Stahl A, Ott K, Weber W A et al. FDG-PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings.  Eur J Nucl Med Mol Imaging. 2003;  30 288-295
    CrossrefPubMedGoogle Scholar
  • 24 Stephens A D, Alderman R, Chang D et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique.  Ann Surg Oncol. 1999;  6 790-796
    CrossrefPubMedGoogle Scholar
  • 25 Sugarbaker P H, Jablonski K A. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.  Ann Surg. 1995;  221 124-132
    PubMedGoogle Scholar
  • 26 Sugarbaker P H, Welch L S, Mohamed F et al. A review of peritoneal mesothelioma at the Washington Cancer Institute.  Surg Oncol Clin N Am. 2003;  12 605-621
    CrossrefPubMedGoogle Scholar
  • 27 Sugarbaker P H. Successful management of microscopic residual disease in large bowel cancer.  Cancer Chemother Pharmacol. 1999;  43 15-25
    CrossrefPubMedGoogle Scholar
  • 28 Sugarbaker P H, Yu W, Yonemura Y. Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer.  Semin Surg Oncol. 2003;  21 233-248
    CrossrefPubMedGoogle Scholar
  • 29 Sugarbaker P H. Management of peritoneal-surface malignancy: the surgeon's role.  Langenbecks Arch Surg. 1999;  384 576-587
    CrossrefPubMedGoogle Scholar
  • 30 Suzuki A, Kawano T, Takahashi N et al. Value of 18F-FDG-PET in the detection of peritoneal carcinomatosis.  Eur J Nucl Med Mol Imaging. 2004;  31 1413-1420
    PubMedGoogle Scholar
  • 31 Tanaka T, Kawai Y, Kanai M et al. Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancer.  Am J Surg. 2002;  184 433-436
    CrossrefPubMedGoogle Scholar
  • 32 Turlakow A, Yeung H W, Salmon A S et al. Peritoneal carcinomatosis: role of (18)F-FDG-PET.  J Nucl Med. 2003;  44 1407-1412
    PubMedGoogle Scholar
  • 33 Valle M, Garofalo A. Laparoscopic staging of peritoneal surface malignancies.  Eur J Surg Oncol. 2006;  32 625-627
    CrossrefPubMedGoogle Scholar
  • 34 Verwaal V J, van Tinteren H, Ruth S V et al. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.  J Surg Oncol. 2004;  85 61-67
    CrossrefPubMedGoogle Scholar
  • 35 Verwaal V J, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.  J Clin Oncol. 2003;  21 3737-3743
    CrossrefPubMedGoogle Scholar
  • 36 Whiteford M H, Whiteford H M, Yee L F et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.  Dis Colon Rectum. 2000;  43 759-767
    CrossrefPubMedGoogle Scholar
  • 37 Yan T D, Haveric N, Carmignani C P et al. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy.  Cancer. 2005;  103 839-849
    CrossrefPubMedGoogle Scholar

Univ. Prof. Dr. A. Königsrainer

Hoppe-Seyler-Straße 3

72076 Tübingen

Phone: +49 / 70 71 / 2 98 66 20

Fax: +49 / 70 71 / 29 55 88

Email: alfred.koenigsrainer@med.uni-tuebingen.de